Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note issued on Friday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. Needham & Company LLC cut shares of Revance Therapeutics from a “moderate buy” rating to a “hold” rating in a report on Tuesday, August 13th. Guggenheim restated a “neutral” rating on shares of Revance Therapeutics in a report on Monday, August 12th. Barclays reaffirmed an “equal weight” rating and issued a $7.00 price target (down from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Stifel Nicolaus reduced their price objective on Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Finally, HC Wainwright lowered Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 13th. Nine analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, Revance Therapeutics has a consensus rating of “Hold” and an average price target of $10.29.

Revance Therapeutics Stock Up 0.2 %

Shares of NASDAQ:RVNC opened at $5.30 on Friday. The company has a market cap of $555.55 million, a P/E ratio of -1.66 and a beta of 0.98. The company’s fifty day moving average is $5.89 and its two-hundred day moving average is $4.30. Revance Therapeutics has a 12-month low of $2.30 and a 12-month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.12. The business had revenue of $65.39 million during the quarter, compared to analysts’ expectations of $66.30 million. During the same period in the prior year, the company posted ($0.80) earnings per share. The firm’s revenue was up 20.2% on a year-over-year basis. Equities research analysts anticipate that Revance Therapeutics will post -1.53 earnings per share for the current year.

Institutional Trading of Revance Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Certuity LLC acquired a new stake in shares of Revance Therapeutics in the second quarter worth $26,000. Creative Planning acquired a new position in Revance Therapeutics during the 3rd quarter worth $56,000. Clarity Capital Partners LLC acquired a new stake in shares of Revance Therapeutics in the first quarter valued at about $59,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Revance Therapeutics in the second quarter worth about $33,000. Finally, Hsbc Holdings PLC bought a new position in shares of Revance Therapeutics in the second quarter worth about $38,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.